Dapagliflozin is a highly selective SGLT2 inhibitor approved for Type 2 Diabetes, heart failure, and chronic kidney disease. It reduces HbA1c levels, body weight, and blood pressur...
Dapagliflozin is a highly selective SGLT2 inhibitor approved for Type 2 Diabetes, heart failure, and chronic kidney disease. It reduces HbA1c levels, body weight, and blood pressure, while offering cardiorenal protective benefits independent of glucose control.
| Parameter | Specification |
|---|---|
| Chemical Name | Dapagliflozin |
| CAS Number | 461432-26-8 |
| Molecular Formula | C₂₁H₂₅ClO₆ |
| Molecular Weight | 408.87 g/mol |
| Purity | ≥ 99.5% |
| Appearance | White to off-white crystalline powder |
| Solubility | Practically insoluble in water |
| Grade | Pharmaceutical Grade |
| Storage | Store below 25°C in dry conditions |
| Batch Size | 10 grams to 250 kg lots |
| Available Documentation | CoA, CoO, DMF, MSDS |
Patent Notice: Products under patents are offered subject to the patent laws of the importing countries. The buyer is solely responsible for compliance with patent rights in any specific country.